William Blair analyst Matt Phipps has maintained their bullish stance on CNTX stock, giving a Buy rating on April 21.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Buy rating due to a combination of factors tied primarily to the prospects of CTIM-76 in ovarian cancer. After meeting with Context Therapeutics’ leadership, he gained confidence that upcoming Phase Ia data, which will include a meaningful number of ovarian cancer patients across the key dose levels, can deliver a response rate around the 30% threshold viewed as clinically compelling.
He also points to the fact that a partial response has already been seen with CTIM-76 and expects the June readout, with detailed efficacy, durability, safety, and biomarker data, to act as a major catalyst for the stock. Given the difficult, heavily pretreated nature of the enrolled ovarian cancer population, any substantial activity would underscore the drug’s differentiation and supports his view that the data could drive a significant revaluation of CNTX shares.
In another report released on April 21, Piper Sandler also maintained a Buy rating on the stock with a $7.00 price target.